Schiller AG and BSP, in Collaboration With University Hospital of Basel, Sign Agreement for the Development of a New Product Line Based on BSP's HyperQ(TM) Technology, in a EUROSTARS Approved Project

BAAR, Switzerland and TEL AVIV, November 22, 2010 /PRNewswire-FirstCall/ -- SCHILLER AG, a leading international manufacturer and supplier of cardiopulmonary diagnostics and BSP Biological Signal Processing Ltd., a medical device company that develops and markets innovative solutions for noninvasive cardiac diagnosis and monitoring , announced on November 8th, 2010 the signing of an agreement to jointly develop a new product line based on BSP's HyperQ(TM) technology. The project will be performed in collaboration with the University Hospital of Basel, one of the premier medical centers in Europe. The project is planned for 3 years with an overall estimated budget of 1.7 Million Euro and will be partly funded by the Swiss and Israeli governments within the prestigious EUROSTARS framework.

The new product line is intended for the lucrative market of resting electrocardiogram (ECG) applications for the early diagnosis and monitoring of myocardial ischemia in patients with suspected acute coronary syndrome, including myocardial infarction (MI). This collaboration comes in continuation to the successful implementation of BSP's HyperQ(TM) Analyzer in Schiller's state of the art CS-200 Excellence machine, a system intended for the stress ECG market, which was launched in Medica 2009.

The HyperQ(TM) technology utilizes advanced signal processing to extract and analyze valuable clinical information from high-resolution ECG signals. Based on solid scientific foundations, and validated in numerous pre-clinical and clinical studies, HyperQ(TM) provides a novel diagnostic tool for the non-invasive diagnosis of ischemic heart disease, with superior accuracy, compared to conventional ECG.

Professor Dr. Christian Muller of University Hospital Basel, clinical principal investigator in the project says: "Accurate, early and low-cost diagnosis or rule-out of suspected acute myocardial ischemia is imperative in order to properly and efficiently triage patients with chest pain, establish their diagnosis and initiate appropriate therapy. The ECG of these patients is often normal or non-diagnostic. Serum biomarkers, regularly-used to identify MI, provide definite diagnosis only hours after the onset of symptoms, when the heart may already have been damaged. The purpose of this project is to develop and study a novel diagnostic tool, utilizing HyperQ-derived technology for improved diagnosis and monitoring of myocardial ischemia".

Mr. Nissim Greisas, CEO of BSP, says that the development of the new product line is the natural next step in the very fruitful collaboration with Schiller. Mr. Greisas also added that the implementation of HyperQ in resting ECG applications will position both companies in a competitive edge in a market that has been very demanding for novel, reliable first line diagnostics for the detection of acute ischemia.

About SCHILLER

SCHILLER is an independent international manufacturer and supplier of electrocardiographs, long-term ECG and blood pressure recorders, spirometers, medical IT solutions, patient monitors and external defibrillators. The company was founded by Alfred E. Schiller in 1974 and has more than 700 employees in 28 subsidiaries around the world. SCHILLER has subsidiaries providing exclusive service centers in 15 countries and representatives in more than 100 countries worldwide.

About BSP

Founded in 2000, BSP is dedicated to providing novel, risk free and highly reliable solutions for the diagnosis and monitoring of cardiovascular disease. BSP's proprietary HyperQ(TM) technology is implemented in cardiac systems that offer accurate and low-cost cardiac monitoring and allows, for the first time, an effective diagnosis of ischemic heart disease in broad populations. BSP is a public company, traded on the Tel Aviv Stock Exchange since 2006 (TASE:BSP). The company's international offices are located in Tel Aviv, Israel and the U.S. offices are in Boston, Massachusetts.

    Contact:

    Nissim Greisas
    CEO, BSP
    [email protected]
    Tel: +972-3-647-4840

SOURCE BSP - Biological Signal Processing Ltd